Glenn J. Hanna

This study tests two different oral drug combinations in people with a rare type of salivary gland cancer called adenoid cystic carcinoma (ACC) that has a specific genetic change (NOTCH mutation). The goal is to see if combining a NOTCH-blocking drug (CB-103) with either abemacic…

This phase 2 trial is testing a combination of three therapies—modified immune cells (PD-L1 t-haNK), an immune-boosting protein (NAI/Anktiva), and a targeted antibody (cetuximab)—in 25 people with recurrent or metastatic head and neck cancer that has not responded to prior immuno…

This study is testing a new immune therapy called RP2, made from a modified herpes virus, to treat high-risk oral precancerous conditions and prevent them from turning into oral cancer. The therapy is injected directly into the lesion. The trial will enroll 25 people and look at …